MedTrace Logo

Vaccine Therapy in Treating Patients With Melanoma of the Eye

NCT00036816 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2012-09-24

No results posted yet for this study

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells and decrease the recurrence of melanoma of the eye.

PURPOSE: Randomized phase III trial to determine the effectiveness of vaccine therapy in treating patients who are at high risk for recurrent melanoma of the eye.

Conditions

  • Intraocular Melanoma

Interventions

BIOLOGICAL

MART-1 antigen

BIOLOGICAL

NA17-A antigen

BIOLOGICAL

gp100 antigen

BIOLOGICAL

tyrosinase peptide

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Vincent Brichard, MD · Cliniques universitaires Saint-Luc- Université Catholique de Louvain

  • Jan U. Prause, MD · University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-02-28
Primary Completion
2003-02-28

Countries

  • Belgium
  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00036816 on ClinicalTrials.gov